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Abstract  
Radiotherapy aims to destroy tumors by inducing DNA damage in their cells at the local 
irradiation site. Its immune-mediated systemic effects, called abscopal effect, has shown to 
enhance anti-tumor immunity when combined with immune therapies and thus, have gained 
attention by researchers and clinicians to investigate. Below is a summary of the fundamentals of 
cancer and the immune system’s response to it, as well as the changes in the phenotype and 
microenvironment of tumor cells after exposure to radiation. Impacts of the abscopal effect and 
the induction of effective antitumor immunity with various immune therapy strategies will be 
outlined. The emphasis is set on combination strategies of local radiation therapy with immune 
therapies such as growth factor inhibitors and immune-checkpoint inhibitors. Limitations 
Finding the most effective immune therapy in conjunction with radiation and optimizing these 
therapies to be more patient-centered, offers the potential to improve anti-cancer treatments in 
the future.   
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Immunization by Radiotherapy: Enhancing an Immune-mediated Abscopal Effect 
Introduction 
Radiotherapy plays a vital role in cancer 
treatment. It not only has the ability to affect 
the DNA of the local tumor, but it also 
produces systemic and immune-mediated 
antitumor immunity (Deloch et al., 2016). 
These effects are enhanced when 
radiotherapy is used in combination with 
other therapies that activate the immune 
system (Frey & Gaipl, 2015). This review 
focuses on the induction of local and 
systemic antitumor immune responses by 
radiotherapy and combined 
immunotherapies. 
The number of cancer incidences is expected 
to increase by over 70% over the next 20 
years, according to the World Health 
Organization (Steward & Kleihues, 2017), 
which presents the need for researchers and 
clinicians alike to find effective antitumor 
treatments.  
Cancer and the immune system 
The basics of cancer 
Cancer is a condition that is manifested by the 
presence of one or another type of neoplastic 
growth—a malignant tumor (Weinberg, 
2014). The cells that make up these 
neoplastic tissues have manipulated the 
versatile and autonomous nature of normal 
cells. These individual cells also gain 
normally denied access to their genomic 
information and adopt roles that are deemed 
inappropriate for maintenance and function 
of normal tissues (Chen & Mellman, 2013). 
Additionally, with increased genomic 
instability, the cell becomes progressively 
susceptible to mutations which can further 
influence an abnormal phenotype. Simply 
put, normal cells function to collaborate with 
each other in order to maintain organismic 
survival. On the other hand, cancer cells care 
little about function and have a more focused 
agenda—growing as much as possible and 
creating more copies of themselves 
(Weinberg, 2014).  
Cancer is a genetic disease that is an 
accumulation of exposure to environmental 
carcinogens and random DNA mutations 
(Chen & Mellman, 2013). Mutations lead to 
a cascade of events that start with a change in 
DNA. Mutated DNA can cause changes in 
the mRNA product which influence changes 
in the amino acid sequences and further 
changes in protein structure and function.  
There are two types of mutations, somatic 
and germ-line. Germ-line mutations are 
inherited mutations, passed down to 
offspring that ultimately increase their 
susceptibility to acquire that type of cancer. 
Somatic mutations are not inherited but 
changes in the DNA sequence caused by 
random mutations accumulated over time 
(Weingberg, 2014). They include two 
categories: loss of function and gain of 
function mutations. Loss of function 
mutations occur in tumor suppressor genes, 
which are specific genes that encode a protein 
that functions to inhibit survival and 
proliferation signals in normal cells. Tumor 
suppressor genes are recessive in nature. 
These recessive genes require two mutates 
copes (one maternal and one paternal) to 
yield a loss of function in the protein, leading 
to the survival and proliferation of cancer 
cells. Gain of function mutations occur in 
proto-oncogenes, which are genes that 
encode a protein that promotes cellular 
growth and survival. Proto-oncogenes are 
dominant in nature and can be activated to an 
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oncogene by a gain of function mutation in 
only one copy of the gene. This leads to 
constitutive activity of the protein and 
continuous downstream signaling of various 
mechanisms of cellular growth (Chen & 
Mellman, 2013). However, even in proto-
oncogenes and tumor-suppressor gene the 
mutations are random events, thus, it is 
possible to speculate that cancer is just a 
combination of mutated susceptible genes 
and unfortunate luck.  
Tumors with the ability to metastasize can 
move around, unrestricted within the 
confines of the body through blood and 
lymphatic vessels and may establish novel 
colonies of cancer cells in distant tissues. The 
newly established colonies, or metastases, 
can be directly traced back to the site where 
the cancer began, termed the primary tumor 
(Formenti & Demaria, 2013). For unknown 
reasons, tumors in certain tissues have a high 
probability of metastasizing and tumors from 
different tissues almost never do. The 
colonization of sites distant to the primary 
tumor is a complex seven-step process 
sometimes referred to as the invasion-
metastasis cascade that relies heavily on 
signals from the surrounding environment 
(Gajewski et al., 2006).  
The tumor microenvironment (TME) houses 
many different types of cells alongside 
cancer cells such as fibroblastic cells, 
lymphocytes, bone marrow-derived 
inflammatory cells, and an extracellular 
matrix (ECM) composed of proteoglycans 
and collagen (Gajewski et al., 2013). The 
discovery that the stromal microenvironment 
of tumors has closely related characteristics 
to normal wounded tissues that do not heal 
has been recognized for over a century 
(Weinberg, 2014). However, the more recent 
discovery concerning its role in stimulating 
an immune response to attach the cancer 
cells, known as adaptive immunity, was 
discovered in 1960 (Schumacher & 
Schreiber, 2015). The former discovery still 
has relevance in that chronic inflammation 
plays a necessary role in promoting tumor 
formation. It has been thought that 
macrophages, a type of inflammatory cell, 
have traditionally been the first line defense 
against invaders where they consume them 
and aid in the cascade of immune cell 
activations through antigen presentation 
(Gajewski et al., 2013). Other than in the 
invasion-metastasis cascade, there is 
evidence that macrophages sent to eradicate 
the invader also function as sources of tumor 
promotion. Their role in tumor promotion 
stems from their production of mitogenic 
growth factors, liberation of angiogenic 
factors, and remodeling of the ECM 
(Gajewski et al., 2006). More and more cells 
of the immune system that are primarily 
released to protect the body from infection as 
well as cancer, are found to be major 
components in the development of the latter. 
Paradoxically, further experiments in mice 
subjected to germ-line reengineering, where 
one or another type of cell form the immune 
system was deleted, resulted in the organism 
being less capable of supporting 
tumorigenesis, and thus was more 
immunogenic (Weinberg, 2014).  
Immune response to cancer 
To be effective in killing cancer cells, the 
immune response mounted against cancer 
cells must initiate a series of events an 
eventually produce the expansion of 
specifically adapted immune cells to their 
target (Frey et al., 2014). In the first step of 
this cycle, neoantigens produced by 
oncogenesis are seized after cancer cell death 
by nonspecific dendritic cells (DCs) and 
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processed. Unless peripheral tolerance to 
these neoantigens is induced, additional 
signals must be present at this step for an 
antitumor T-cell response to be mounted. 
These signals can include various pro-
inflammatory cytokines and factors released 
from dying cancer cells (Schumacher & 
Schreiber, 2015). After processing, The DCs 
present the antigen on their MHCI and 
MHCII molecules to the T-cell receptors 
(TCRs) of helper and cytotoxic T-cells. This 
binding, along with other expressed 
complimentary costimulatory molecules, 
enables the priming of effector T-cells and 
subsequent activation. This results in effector 
T-cell responses against cancer-specific 
antigens viewed as non-self or against those 
from incomplete central tolerance (Reits et 
al., 2006). The activated T-cells that 
complete central tolerance travel from the 
lymph node through lymph and blood vessels 
to infiltrate the tumor bed, where it will 
specifically recognize and bind it’s TCR 
MHCI of the target cancer cell and kill it. The 
killing of cancer cells releases more tumor 
antigens that then stimulates an increased 
immune response that ultimately promotes a 
faster and more specific response in 
subsequent response cycles (Weinberg, 
2014). However, this cycle does not always 
yield effective T-cell killing machines. For 
example, tumor antigens may not be 
detected, and/or they might be recognized as 
self rather than non-self, resulting in T 
regulatory cell (Treg) responses rather than 
effector T-cell responses (Chen & Mellman, 
2013).  
The derivation of the antigens that permit the 
immune system to differentiate malignant 
cells from nonmalignant cells has been 
unknown for a long time (Tureci et al., 2016).  
However, we do know that the body’s T-cell 
repertoire can recognize peptide epitopes on 
the surface of malignant cells via the highly 
specific major histocompatibility complexes 
(MHCs). The theoretical explanations for the 
origin on these cancer rejection epitopes 
involve the derivation from two classes of 
antigens (Schumacher & Schreiber, 2015). 
The first class of possible antigens is made by 
non-mutation proteins to which incomplete 
T-cell tolerance occurs due to their limited 
tissue expression pattern. The second class of 
possible cancer rejection antigens are made 
from peptides that are completely absent 
from the normal human genome—
neoantigens. The large group of human 
tumors without a viral etiology are 
exclusively created by tumor-specific 
alterations in DNA that produce new protein 
sequences (Schumacher & Schreiber, 2015).  
The repertoire of neoantigens expressed in 
cancer at the point it is clinically apparent 
may be influenced substantially by the 
interaction of the developing tumor with the 
immune system (Schumacher & Schreiber, 
2015).  Cancer progresses and develops in the 
body in three phases. During the first phase, 
the immune system senses tissue changes 
during neoplastic transformation and releases 
chemicals, such as cytokines, to alert other 
immune cells to the area. Here, the innate and 
adaptive immune responses recognize the 
transformed tissue and attempt to eradicate it 
before it become clinically detectable This is 
the elimination phase (Whiteside, Demaria, 
Rodriguez-Ruiz, Zarour, & Melero, 2016).  If 
elimination is incomplete, the cells that 
survived the initial immune response have 
generated escape mutants due to genomic 
instability. However, tumor proliferation is 
equal to tumor killing and, is thus, called the 
equilibrium phase. To tip the scales in favor 
of tumor survival and proliferation, the 
tumor’s neoantigens and associated epitopes, 
recognized by T-cells, are constantly 
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generated. This leads to the escape phase, 
where a loss of more immunogenic antigens 
causes the immune system to no longer 
mount an effective killing response (Derer et 
al., 2015). Thus, the tumor acquires 
resistance to immune rejection and now can 
be clinically detectable  Therefore, strategies 
such as radiotherapy, which mediates the 
immunogenic release of tumor antigens, 
along with ways to upset the body’s natural 
immunosuppressive dominance, provide the 
environment to recover the efficacy of 
immunotherapies (Whiteside et al., 2016) 
Abscopal Effect 
Local radiation promotes systemic 
antitumor vaccine 
The application of local radiotherapy, in 
combination with targeted immunotherapies, 
where the radiation acts as an antitumor 
vaccine on tumors outside the radiation field, 
is a phenomenon known as the abscopal 
effect (Reynders, Illidge, Siva, Chang, & De 
Ruysscher, 2015).  First proposed by Mole in 
1953, the term “abscopal effect” was derived 
from the Latin “ab” (away from) and 
“scopos” (target), referring to the systemic 
effects of local radiation on distant 
nonirradiated tumor sites in animals after 
treatment. (Mozdarani, 2012). This rare but 
well-documented event represents a 
paradigm shift in cancer therapy—some 
effects of radiation are seen as beneficial and 
contribute to the regression of the local 
primary tumor as well as its metastases 
(Formenti & Demaria, 2013). 
The generalized objective of radiotherapy is 
to deposit maximum dose of ionizing 
radiation in the tumor while sparing healthy 
tissue (Demaria, Golden, & Formenti, 2015). 
Radiation uses localized beams of intense 
energy to cause catastrophic DNA damage 
which produces highly radical oxygen 
species (ROS) that further damage DNA. The 
DNA damage checkpoint then arrests the 
tumor cell from advancing through the cell 
cycle and employs repair pathways (Deng et 
al., 2014). If the various DNA damage 
response mechanisms are unable to 
compensate the damage, tumor cell death 
occurs. The apoptotic tumor remnants are 
phagocytized by nonspecific, antigen-
presenting cells (APCs) in the area and 
presented on their MHC class I molecules to 
await adaptive immune cells (Derer et al., 
2015). 
Other non-apoptotic tumor cells at the 
irradiated site still undergo DNA damage but 
are either unable to sense the damage or are 
unable send the signal due to prior mutations 
that inhibit these steps. Therefore, when the 
tumor cell machinery senses this damage, 
instead of signaling apoptosis, it releases 
signals like damage-associated molecular 
patterns (DAMPs), pathogen-associated 
molecular patterns (PAMPs), and 
chemokines to enlist the help of 
inflammatory cells to the TME (McBride et 
al., 2004). The proinflammatory modifiers 
responsible for recruiting effector cytotoxic 
and helper T-cells are the chemokines 
CXCL9, CXCL10 and CXCL16 and the 
cytokines interleukin 1β tumor necrosis 
factor α (TNF-α) and interferon γ (IFN-γ) 
type 1 and 2 (Lugade et al., 2008).  TNF-α 
and IFN-γ also promote the maturation and 
cross-presentation of DC’s. As these help 
signals are being sent, tumor cells undergo 
changes in their phenotype that augment their 
susceptibility to and recognition by recruited 
immune effectors. Some of these phenotypic 
changes include the increased expression of 
death receptors, MHC class I molecules, 
costimulatory molecules, adhesion molecule 
and stressed induced ligands (Reits et al., 
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2006).  primes the tumor cells which allows 
them, and the already primed APCs to 
communicate with the recruited B- and T-
lymphocytes to activate their effector 
functions.  
Various mechanisms have been proposed to 
explain the abscopal effects of radiotherapy. 
While we know that radiation causes 
inflammation that induces the activation of 
antigen-presenting DCs (Gupta et al., 2012), 
the integral events leading up to the final 
effect, are poorly understood. Patient specific 
tumor heterogeneity and unpredictability as 
well as the individualized immune response 
to the tumor, further complicate our 
understanding of the necessities for induction 
(Tureci et al., 2016). Although, recent studies 
have shown that an adaptor protein known as 
the stimulator of interferon genes (STING), a 
main contributor in innate immunity, is one 
requirement for the antitumor effect of 
radiation and the introduction of type I IFNs 
(Deng et al., 2014). Adaptor proteins are 
responsible in intracellular signaling 
pathways where they regulate gene 
transcription. In regards to cancer, the 
STING pathway operates by using its 
cytoplasmic pattern recognition receptor to 
sense radiation-induced, tumor-released 
DNA (Rodriguez-Ruiz et al., 2016). The 
importance of type I IFNs has been 
elucidated by the prior research of Burnette et 
al. (2011) testing mice either lacking or not, 
the type I IFN receptor (IFNAR-/-). They 
found that cytotoxic T-cell function depends 
on their radiation-induced presence in the 
TME. As mentioned before, IFNs are a class 
of proinflammatory proteins that enhance 
cross-presentation to activate the specific 
adaptive immune response. The STING 
pathway bridges that gap between innate and 
adaptive immunity and in response to 
radiation, is crucial for the spontaneous 
generation of antitumor T-cell responses 
against immunogenic tumors (Woo et al., 
2015). However, the diverse range of stimuli 
needed to generate type I IFN production, as 
seen in the various nucleic acid-sensing 
pathways, together with the unknown 
identity of immune cells that carry out type I 
IFN responses after radiation, exemplify the 
difficulties of inducing the abscopal effect. 
Recent data suggest that radiotherapy 
increases these responses, thereby providing 
a potential explanation to this rather elusive 
event (Deng et al., 2014).  
The uncommon occurrence of abscopal 
effects observed in cancer patients reflects 
only one barrier to effective tumor rejection. 
For cytotoxic T-cells to reject a tumor, a set 
of sequential steps must be followed.  First, 
T-cells must be able to home correctly to the 
tumor site by extravasating from vessels to 
access the tumor microenvironment. 
Secondly, it is imperative for T-cells to retain 
their effector functions once they arrive at the 
tumor site. Lastly, stable immunological 
synapses must be established between the 
tumor cell and the effector T-cell (Gajewski 
et al., 2006).  In each of these steps, there are 
multiple obstacles to overcome due to the 
complex nature of signaling pathways and 
their messengers.  
Another critical barrier to priming of T-cell 
responses to various tumor antigens, induced 
by radiotherapy, is the protein known as 
transforming growth factor beta (TGFβ) 
(Kang, Demaria, & Formenti, 2016). This 
cytokine is important in promoting the 
differentiation of immunosuppressive T-cell 
subsets, like regulatory T-cells (Tregs) which 
mediate immune responses from becoming 
harmful to the body. Therefore, when ROS 
are produced as a consequence of 
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radiotherapy, they convert latent TGFβ to its 
active form (Vanpouille-Box et al., 2015). 
While radiation promotes the release of pro-
immunogenic signals to the tumor site, it also 
promotes immunosuppressive mechanisms. 
Therefore, its ability to induce an immune-
mediated abscopal effect most likely depends 
on altering the pre-existing tumor 
microenvironment to shift the balance to 
favor an immunostimulatory one (Gajewski 
et al., 2013). Despite how the positive effects 
of radiation generally outweigh the negative 
effects, without targeted immunotherapy, 
radiation alone is not insufficient to shift the 
balance to accomplish tumor rejection and 
control metastatic progression (Formenti & 
Demaria, 2013). The therapeutic applications 
of radiotherapy as well as chemotherapy, 
whether stand-alone or in conjunction with 
targeted immunotherapies, should stimulate 
local and systemic tumor control by the 
promotion of immunogenic cell death, which 
can induce persistent antitumor responses by 
the immune system. (Gaipl et al., 2014).  
Effects enhanced by combination 
strategies  
The application of ionizing radiation to 
cancer therapeutics has long been established 
due to the combination of its cytocidal 
influence and selectivity in targeting tumors 
(Demaria et al., 2015).  However, in the past 
two decades, the concept was proposed to 
combine local radiation treatment with 
immunotherapy to induce an abscopal effect 
focused on inhibiting metastatic growth 
(Shiraishi et al., 2008).  
Combination strategies from these clinical 
trials utilized targeted immunotherapies to 
enhance the effects of radiation, such as 
influencing either the priming or effector 
phases of antitumor immune responses 
(Formenti & Demaria, 2013).  In one study, 
cross-priming of antitumor T cells was 
enhanced by the amplification of DC number 
and function. This was demonstrated in mice 
by the administration of DC growth factors 
such as Flt3-ligand near the irradiated tumor 
and by the injection of exogenously prepared 
syngeneic DCs into the irradiated tumor for 
which inhibition of spontaneous metastases 
was observed in a lung carcinoma and breast 
cancer, respectively (Chakravarty et al., 
1999). In a phase I trial, patients with hepato-
cellular carcinoma were intratumorally 
injected with autologous DCs 2 days after 
single fraction radiotherapy and a partial 
abscopal response was seen in two out of 14 
patients (Chi et al., 2005). In another study, 
DCs injected into sarcomas during 
fractionated radiotherapy, showed infiltration 
of T-cells in the tumor at the time of surgery 
with tumor-specific immune responses from 
nine out of the 17 patients. A year later, 12 
out of the 17 patients were progression-free 
of their cancer (Finkelstein et al., 2012).  
According to Hildner et al., cross-
presentation to cytotoxic T-cells are mainly 
regulated by a specialized subset of DCs that 
depend on Baft-3 transcription factor and 
Flt3-ligand as a growth factor for their 
development (2008). Experiments to test 
Baft-3-dependent DCs on the induction of 
antitumor cytotoxic T-cells in Baft-3-
deficient mice revealed a loss of the abscopal 
effect and a diminished control of the local 
tumor. This suggests, to some extent the 
critical role of IFNα/β on the therapeutic 
effects from radiotherapy. Similarly, BATF-/- 
and IFNAR-/- mice lost the radiation-induced 
abscopal effects when treated with the 
combination of anti-PD1 and anti-CD137 
monoclonal antibodies, or mAbs (Rodriguez-
Ruiz et al., 2016). In addition, strategies 
focused on the enhancing the local induction 
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of IFNα/β have potential to elicit more 
immunogenic tumor cell deaths induced by 
combination treatments with radiotherapy. 
The immunogenic cell death induced by 
radiotherapy, however, only offers temporary 
systemic control and may be due to the weak 
immunization effects or because of factors 
and mechanisms such as TGFβ that work in 
tandem to suppress the immune system 
(Vanpouille-Box et al., 2015). For example, 
strategies tested in preclinical and clinical 
trials to block TGFβ combined with 
radiotherapy, have the potential to counteract 
its immunosuppressive effects and to also 
thwart DNA damage repair, angiogenesis, 
and metastasis (Bouquet et al., 2011).  
Strategies to promote the effector phase of 
antitumor immunity have coupled T-cell 
activation with an antibody that targets the 
inhibitory checkpoint receptor CTLA-4 
(cytotoxic T lymphocyte-associated antigen 
4) after radiation therapy (Kang et al., 2016).  
Currently being developed in the clinic, 
mAbs that target receptors on immune cells 
where they either remove coinhibitory 
signals or supply costimulatory signals to 
improve antitumor immunity. The 
combination of ipilimumab (an anti-CTLA-4 
mAb) with radiotherapy currently has limited 
clinical experience as there are only results 
from two clinical trials that are now available 
for prostate cancer and metastatic melanoma 
(Twyman-Saint Victor et al., 2015).  In a 
preclinical study using anti-CTLA-4 mAbs, it 
was shown that simultaneous positive 
costimulation with inhibition of negative 
costimulatory signals increased the avidity by 
10-fold. Wherein, avidity is the concentration 
of antigen required to elicit a T-cell response 
after target loading (Poleszczuk et al., 2016). 
Results from prospective clinical trials 
combining radiotherapy with anti-CTLA has 
shown success in non-small cell lung 
carcinoma (NSCLC). According to Golden et 
al. (2015), since NSCLC is a tumor type that 
is unresponsive when give anti-CTLA-4 
alone, this gives hope that multiple tumor 
types might also benefit from the 
radiotherapy combinations.  
Conclusion 
Radiotherapy induces an immune-mediated 
abscopal effect which is further enhanced 
with the combination of immunotherapy to 
produce a systemic antitumoral vaccine. 
Targeted immunotherapies using growth 
factor inhibitors and antibodies such as TGFβ 
and anti-CTLA-4, respectively, have 
reported effective antitumor induction (Derer 
et al., 2015). Overall, these studies show 
combination strategies are more effective 
than any one strategy alone and may be 
applicable to multiple cancer types in the 
future.  
Limitations 
As mentioned above, one of the challenges 
that researchers face is finding treatments 
that promote tumor immunogenicity and 
simultaneously hinder immunosuppression. 
It is also crucial to gain knowledge on the 
specific mechanisms and mediators involved 
in the induction of an immune-mediated 
abscopal effect, such as understanding 
STING pathway, as well as information on 
the identify and function of the specialized 
subset of DCs responsible for T-cell cross-
presentation (Kang et al., 2016). 
Additionally, a more patient-specific 
treatment could prove more effective when 
considering their specific tumor type, stage of 
progression, and immune cell repertoire. 
Further investigation is needed to find the 
optimal timing, dose and fractionization of 
radiotherapy with combination strategies and 
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how they depend the type of immunotherapy 
used (Rodriguez-Ruiz et al., 2016). 
Future Research 
In general, strategies using radiotherapy to 
induce systemic antitumor immunity, are 
being tested in various preclinical trials, in 
combination with immunomodulatory 
interventions that either block 
immunosuppressive mechanisms or enhance 
immune response activation. However, there 
is much to be known about the effects of 
targeting key activators or suppressors of the 
immune system after radiation. Thus, 
prospective research should focus on 
combining multiple immune mediators with 
radiation to augment the primer and effector 
phases of antitumor immunity. These include 
likely targets such as Baft-3, Flt3-ligand, 
IFNα/β, TGFβ, anti-PD1, and anti-CTLA-4 
(Deloch et al., 2016). 
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Appendix A 
American Psychological Associated (APA) 6th edition was the format style used for this 
literature review. According to the APA Publication Manual, the Title page should include a 
running head, a title, the author’s name and the institutional affiliation. Following the Title page 
is the Abstract, that is written as a single paragraph of 150-250 words. Next, the Table of 
Contents page, where the first level is bold, centered, including upper and lowercase letters. The 
second level headings are bold, left-aligned and capitalized first letter. The body contains the 
introduction, discussion and conclusion that uses 12-point, Times New Roman font with the 
paragraphs aligned to the left. A shortened version of the title of the paper was used as a header 
for all subsequent pages after the title page. The References page appears at the end of the 
document and includes references with a hanging indent. The in-text citations include the author 
and the year of publication.  
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Appendix B 
In the process of editing my original version, I decided to restart my literature review paper with 
a more focused topic and thus, documentation of feedback from my external reviewer was 
unattainable. However, peer-reviewed suggestions were taken into consideration and most were 
accepted.  
